Glaxo Group Limited

Smithkline Beecham Corporation

Other

Glaxosmithkline LLC

Andrew McMurtrie Mason

Alan D Borthwick

Nigel Stephen Watson

Chuen Chan

Henry Anderson Kelly

John Liddle

Deirdre Mary Bernadette Hickey

Robert John Young

Nigel Paul King

Stefan Senger

Julie Nicole Hamblin

Vipulkumar Kantibhai Patel

Gita Punjabhai Shah

Caroline Whitworth

Helen Elisabeth Weston

Neil Derek Miller

Paul Graham Wyatt

Gerard Martin Paul Giblin

Anna Katrin Szardenings

Steven Leslie Sollis

David George Hubert Livermore

Richard Jonathan Hatley

Fabrizio Nerozzi

Ann Louise Walker

Savvas Kleanthous

Susan Roomans

Miles Stuart Congreve

Ivan Leo Pinto

Xiao Qing Lewell

Simon John Fawcett MacDonald

Matthew Campbell

Graham George Adam Inglis

Derek Anthony Demaine

Paul William Smith

Martin Edward Swarbrick

Keith Watson

Rachel Elizabeth Hosking

Stephen Edward Shanahan

Haydn Terence Jones

Darryl McConnell

Simon John Fawcett Macdonald

Betty Jin

Michael Dennis Dowle

Wen-Yang Wu

Richard Jonathan Daniel Hatley

Compounds of formula (I) wherein Ris 2-indanyl, Ris 1-methylpropyl, Ris a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, Rrepresents methyl and Rrepresents hydrogen or methyl or, Rand Rtogether with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.

Compounds

A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a human in need thereof of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.

Substituted diketopiperazines as oxytocin antagonists

A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a human in need thereof of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Compounds of formula (I) wherein Ris 2-indanyl, Ris 1-methylpropyl, Ris a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, Rrepresents methyl and Rrepresents hydrogen or methyl or, Rand Rtogether with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.

The present invention relates to a xanthine compound derivative which is 3-butyl-8-chloro-1-(3-{5-[(4-fluorophenyl)methyl]-2H-tetrazol-2-yl}propyl)-3,7-dihydro-1H-purine-2,6-dione: a pharmaceutically acceptable salt thereof, corresponding pharmaceutical formulations, combinations, preparation methods and methods or uses in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.

Xanthine derivatives as selective HM74A agonists

Naphthalene derivatives

Piperazinediones as oxytocin receptor antagonists

The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

Pyrrolidine derivatives as factor Xa inhibitors

A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a mammal in need thereof of an effective amount of a compound of the formula (I) and/or a physiologically acceptable derivative thereof, wherein the substituents have the meaning given in the description. Disclosed are also novel compounds of formula (I) and processes for their preparation.

The invention relates to compounds of formula (I): wherein substituents are as defined.

1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor Xa inhibitors for the treatment of acute vascular diseases

Pyrrolidine derivatives as factor XA inhibitors

Compounds of formula (I) or salts or solvates thereof or physiologically functional derivatives thereof are potent binders at the EP4 receptor and are of use in the treatment or prevention of conditions such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

Indole derivatives

Growing community of inventors

Stevenage, United Kingdom

Andrew McMurtrie Mason